

Günther Wollein and Reinhard Troschütz*

Department of Medical Chemistry, Emil Fischer Center, Friedrich–Alexander University,
Schuhstr.19, D-91052 Erlangen, Germany
Received April 29, 2002

Dedicated to Professor Kurt Eger (Leipzig) on the occasion of his 60th birthday

o-Aminoamide **8**, an intermediate in our multistep synthesis of the title compounds was prepared from 1,3-diketone **3**. The following condensation of **8** with chloroformamidine-HCl (**9**) gave pyrido[3,4-*d*]pyrimidine **10**. Dehydration of amide **8** led to *o*-aminonitrile **15**, which was cyclocondensated with guanidine (**16**) to yield pyrido[3,4-*d*]pyrimidine-2,4-diamine **17**. Coupling of the acids **11** and **18** with diethyl L-glutamate (**12**) and following saponification provided 7-aza-5,8,10-trideazafolic acid **14** and its 4-amino-derivative **20**.

J. Heterocyclic Chem., **39**, 1195(2002).

In the last decades many efforts have been made to obtain structural variations of folic acid as possible antitumor agents with antifolate activity [1].

As a result, some very promising attempts lead to methotrexate (MTX) (inhibition of mammalian dihydrofolatereductase) [2], which had already been synthesized in 1947, but is still the method of choice in the treatment of mammalian carcinoma in a combination therapy. More recent compounds with antitumor potency are pemetrexed [3] (mainly inhibition of thymidilate synthetase) [4] and lometrexol (inhibition of glycineamideribonucleotid-formyltransferase) [5], which are currently under investigation in clinical trials.



Unfortunately each of these therapeutic agents have disadvantages. Beside the common toxicity for healthy cells,

some types of cancer have a naturally or acquired resistance against methotrexate [6], or – in the case of lometrexol – a cumulative toxicity [7]. For that reason it is necessary to synthesize new structural variations of antifolates having a better activity – toxicity ratio than do the existing ones.

With this intention we have planned to modify the pyrido[2,3-*d*]pyrimidine nucleus, which is present in the non classical antifolate piritrexim [8] and lometrexol. We formally shifted N⁸ to position 7 in order to modulate the polarity and basicity of the anellated pyridine ring and come to a pyrido[3,4-*d*]pyrimidine as the basic heterobicycle for new antifolates, on one hand 4-amino-4-deoxy-7-aza-5,8,10-trideazafolic acid (**20**) with structural similarity to methotrexate, on the other hand 7-aza-5,8,10-trideazafolic acid (**14**), which in our opinion could possess antitumor activity.

In literature only a pterotic acid analogue exists with a pyrido[3,4-*d*]pyrimidine structure [9].

Generally only few entries to substituted pyrido[3,4-*d*]pyrimidines have been described and most of the existing routes did not seem suitable for our synthesis of 6-alkyl-substituted derivatives.[10–13]. A short retrosynthetic view, which explains our approach is outlined in scheme 2.



Cleavage of strategic bonds in the target compound 7-aza-5,8,10-trideazafolic acid (**14**) leads to a 3-amino-isonicotinic acid derivative as the key intermediate and guanidine. Further retrosynthesis gives rise to a 3-nitropyridine that could originate from a nitroendiamine and a 1,3-diketone [14].


One recent access to 3-amino-6-chloroisonicotinic acid exists in the directed lithiation of boc-protected 6-chloro-

pyridine-3-ylamine with butyllithium followed by quenching with carbon dioxide [15]. We used this reaction with a boc-protected 6-styrylpyridine-3-ylamine as a model compound, but unfortunately did not get the desired 3-amino-6-styrylisonicotinic acid.

For this reason we decided to tread an alternative path.

Improving the method of Maguire and McKee [9], who synthesized ethyl 6-methyl-3-nitro-2(1*H*)pyridone-4-car-

Scheme 3



boxylate as a precursor of a 3-aminoisonicotinic acid derivative from nitroacetamide and ethyl acetopyruvate in a low yield of 13 %, we replaced nitroacetamide by 2-nitroethene-1,1-diamine (**4**) (Scheme 2) – in our hands a versatile building block for an easy entry to 3-nitropyridine-2-amines [16,17].

Our sequence for the synthesis of 7-aza-5,8,10-trideazafolic acid (**14**) starts with the preparation of the necessary 1,3-biselectrophile ethyl 4-(5-ethoxycarbonyl-3,5-dioxopentyl)benzoate (**3**) from claisen condensation of ketone **1** with diethyl oxalate (**2**) [18] which proceeds in good yields after purification by Kugelrohr distillation.

The following cyclocondensation [16] of 1,3-diketone **3** with 2-nitroethene-1,1-diamine (**4**) was carried out in methanol under reflux. Of the two possible regioisomers – *i.e.* the isonicotinic acid derivative **5** and/or the α -picolinic acid derivative – we only isolated the desired 3-nitroisonicotinate **5** in a yield of 65% without further necessary purification. The isonicotinic ester structure of **5** was proved by heteronuclear bond correlation (hnbc). Only one coupling signal from the C1-hydrogen of the ethylene chain to the pyridine-C5 was detected. In case of the isomeric α -picolinic acid derivative, two correlation signals from C1-hydrogen of the ethylene bridge to C3- and C5 of the pyridine nucleus should have been observed.

The thus obtained 3-nitroisonicotinate **5** could be directly and efficiently converted to the 2-chloropyridine derivative **6** by substitutive deamination [19] with *tert*-butyl nitrite and anhydrous copper(II) chloride in dry acetonitrile.

Subsequent hydrogenation of 2-chloropyridine derivative **6** at atmospheric pressure resulted in the reduction of the nitro group and hydrogenolysis of the 2-chloro substituent, affording 3-aminoisonicotinate **7** in a yield of 58%.


However, having no success in hydrogenation of **6** with a palladium on barium carbonate catalyst, we found palladium on charcoal 10% [20]- with a small amount of triethylamine – to be the exceptional catalyst.

The direct pyrimidine annellation to 2-amino-4-oxopyrido[3,4-*d*]pyrimidine **10** from *o*-aminoester **7** and guanidine or chloroformamidine-HCl [21] in various solvents and a variety of temperatures failed.

We solved the problem by treating of **7** with ammonia in methanol. The ammonolysis of **7** gave rise to *o*-aminoamide **8** (60%) and a diamide (15%), which were separated by column chromatography. The following ring closure of **8** with chloroformamidine hydrochloride in dimethylsulfone at 160 °C provided **10** [21], indicating that an *o*-aminoamide group has been formed by ammonolysis of **7**.

Saponification of **10** [22], followed by coupling of the resulting benzoic acid derivative **11** with diethyl L-glutamate

Scheme 4



(12) using 6-chloro-2,4-dimethoxy-1,3,5-triazine/*N*-methylmorpholine [23], gave rise to L-glutamate derivative 13.

Final alkaline hydrolysis of 13 followed by acidification with acetic acid yielded the target compound *N*-[4-[2-(2-amino-4-oxopyrido[3,4-*d*] pyrimidin-6-yl)ethyl]benzoyl]-L-glutamic acid (14).

The starting sequence for the synthesis of *N*-[4-[2-(2,4-diaminopyrido[3,4-*d*] pyrimidin-6-yl)ethyl]benzoyl]-L-glutamic acid (20) is equal to that of L-glutamic acid derivative 14.

In order to generate a amino function instead of the oxo function in position 4 of a pyrido[3,4-*d*]pyrimidine derivative 20 it was necessary to convert the 3-aminoisonicotinamide 8 into 3-aminoisonicotinonitrile 15.

Several attempts to prepare 15 by treatment of isonicotinamide 8 with cyanuric chloride [24], methyl (carboxysulfamoyl) triethylammonium hydroxide inner salt (Burgess reagent) [25] or POCl₃ [26] failed. In the end we achieved the nitrile 15 by using trifluoroacetic anhydride and excess triethylamine in tetrahydrofuran [27].

Ring closure of *o*-aminonitrile 15 to pyrido[3,4-*d*]pyrimidin-2,4-diamine 17 was done successfully by reaction with guanidine in dimethylsulfone at 130 °C [28].

Saponification of benzoate 17 [22], followed by coupling of the resulting benzoic acid 18 with diethyl L-glutamate (12) using 6-chloro-2,4-dimethoxy-1,3,5-triazine/*N*-methylmorpholine [23], gave the intermediate L-glutamate derivative 19.

Final alkaline hydrolysis of 19 followed by acidification with acetic acid yielded the MTX analogue *N*-[4-[2-(2,4-diaminopyrido[3,4-*d*] pyrimidin-6-yl)ethyl]benzoyl]-L-glutamic acid (20).

EXPERIMENTAL

Melting points were determined on a Lindström capillary melting point apparatus from Büchi (type 530) and are uncorrected. The ir spectra were recorded on a Perkin-Elmer infrared-fourier-transform-spectrophotometer (type 1740). The ¹H nmr spectra and the ¹³C nmr spectra were recorded on ft-nmr spectrometers: Bruker AC 250 (at 250.13 MHz), Bruker AM 360 (at 360.13 MHz). The ¹³C nmr spectra were recorded at 60.6 and 90.6 MHz; the solvent was dimethylsulfoxide-*d*₆ (unless otherwise stated) with tetramethylsilane as the internal standard. The uv spectra were recorded on a Perkin-Elmer spectrophotometer (type Lambda 5). Solvent was methanol (UVasol, Merck). Mass spectra were recorded on a Finnigan TSQ 70 (electron; ionisation energy 70 eV) and JEOL MS 700 (field desorption). Microanalyses were carried out on a Carlo Erba Elemental Analyzer Model 1106.

Ethyl 4-(5-Ethoxycarbonyl-3,5-dioxopentyl)benzoate (3).

To a stirred and cooled (0 °C) solution of 1.15 g (50 mmoles) sodium in 50 ml ethanol a mixture of 11 g (50 mmoles) ethyl 4-(3-oxobutyl)benzoate (1) and 14.6 g (100 mmoles) diethyl oxalate (2) was added dropwise. After standing at room temperature overnight, it was neutralized with an equimolar amount of glacial

acetic acid and poured on 300 ml ice. After extracting with ether (3 x 300 mL), the combined organic layers were washed with water, dried over sodium sulfate and evaporated to give 12 g (75%) of a colourless oil after distillation by Kugelrohr-apparatus; bp 140 °C (5*10⁻² bar); ir (sodium chloride): 2985, 2938 and 2908 (CH), 1716 (ester CO), 1639 and 1608 cm⁻¹ (ketone CO); ¹H nmr (dimethylsulfoxide-*d*₆): δ 1.26-1.34 (m, 6H, 2x OCH₂-CH₃), 2.97 (s, 4H, CH₂-CH₂), 3.62 (s, 2H, O=C-CH₂-C=O), 4.23-4.34 (m, 4H, 2x OCH₂-CH₃), 7.37-7.43 (m, 2H, 3-H and 5-H), 7.84-7.92 ppm (m, 2H, 2-H and 6-H); ms: m/z 321 (M+1).

Anal. Calcd. for C₁₇H₂₀O₆: C, 63.75; H, 6.29. Found: C, 63.92; H, 6.39.

Ethyl 2-Amino-6-[2-(4-ethoxycarbonylphenyl)ethyl]-3-nitroisonicotinate (5).

A mixture of 980 mg (3 mmoles) ethyl 4-(5-ethoxycarbonyl-3,5-dioxo-pentyl)benzoate (3) and 320 mg (3 mmoles) 2-nitroethene-1,1-diamine (4) in 20 ml methanol was heated at reflux for 45 minutes and cooled to room temperature. Dropwise adding of water provided 755 mg (65%) of 5 as a bright yellow solid. mp 122-123 °C; ir (sodium chloride): 3521, 3455, 3382 and 3270 (NH₂), 2989, 2931 and 2865 (CH), 1720 (ester CO), 1631, 1565 and 1504 cm⁻¹ (NO₂); uv (methanol): λ_{max} 390 nm (ε 6733); ¹H nmr (dimethylsulfoxide-*d*₆): δ 1.26 (t, J = 7.1 Hz, 3H, OCH₂-CH₃), 1.31 (t, J = 7.1 Hz, 3H, OCH₂-CH₃), 2.96-3.10 (m, 4H, CH₂-CH₂), 4.29 (q, J = 7.1 Hz, 4H, 2x OCH₂-CH₃), 6.72 (s, 1H, 5-H), 7.37-7.41 (m, 2H, 3'-H and 5'-H), 7.85-7.90 (m, 2H, 2'-H and 6'-H), 7.95 ppm (broad s, 2H, NH₂ deuterium oxide exchangeable); ms: m/z 387 (M⁺).

Anal. Calcd. for C₁₉H₂₁N₃O₆: C, 58.92; H, 5.46; N, 10.85. Found: C, 59.03; H, 5.46; N, 10.81.

Ethyl 2-Chloro-6-[2-(4-ethoxycarbonylphenyl)ethyl]-3-nitroisonicotinate (6).

tert-Butyl nitrite (0.36 ml, 3 mmoles) was added to a stirred suspension of 322 mg (2.4 mmoles) anhydrous CuCl₂ in 30 ml anhydrous acetonitrile. The mixture was heated at 65 °C and then a solution of 330 mg (0.86 mmoles) 5 in 30 ml anhydrous acetonitrile was added over a period of 5 minutes to the reaction medium. During the addition the mixture turned completely black from the initial green colour. After complete gas evolution (~ 15 minutes) the temperature was allowed to come to room temperature and the mixture was poured into 50 ml 20% aqueous HCl. Ethyl acetate (60 ml) was added and the organic phase separated, washed with 50 ml 20% aqueous HCl and dried (Na₂SO₄). The solvent was removed under reduced pressure and 6 was crystallized from methanol (0 °C) in a yield of 60% as colourless solid; mp 103-104 °C; ir (sodium chloride): 3066, 2992 and 2935 (CH), 1743 and 1700 (ester CO), 1592 and 1546 cm⁻¹ (NO₂); ¹H nmr (dimethylsulfoxide-*d*₆): δ 1.27 (t, J = 7.1 Hz, 3H, OCH₂-CH₃), 1.31 (t, J = 7.1 Hz, 3H, OCH₂-CH₃), 3.06-3.14 and 3.22-3.29 (m, 4H, CH₂-CH₂), 4.29 (q, J = 7.1 Hz, 2H, OCH₂-CH₃), 4.34 (q, J = 7.1 Hz, 2H, OCH₂-CH₃), 7.40-7.44 (m, 2H, 3'-H and 5'-H), 7.86-7.91 (m, 2H, 2'-H and 6'-H), 7.95 (s, 1H, 5-H); ms: m/z 406 (M⁺).

Anal. Calcd. for C₁₉H₁₉N₂O₆Cl: C, 55.86; H, 4.69; N, 6.86. Found: C, 55.68; H, 4.98; N, 6.83.

Ethyl 5-Amino-2-[2-(4-ethoxycarbonylphenyl)ethyl]-isonicotinate (7).

To a solution of 100 mg (0.25 mmoles) 6 and 0.1 ml triethylamine in 8 ml ethanol was added 100 mg 10% palladium on

carbon and the mixture was hydrogenated for 2 hours under atmospheric pressure. The catalyst was filtered off and the filtrate was evaporated nearly to dryness. Storing at 0 °C yielded 60 mg (70%) colourless needles. mp 132 – 133 °C; ir (potassium bromide): 3451 and 3337 (NH₂), 2976 and 2937 (CH), 1712 cm⁻¹ (ester CO); ¹H nmr (dimethylsulfoxide-d₆): δ 1.26-1.34 (m, 6H, 2x OCH₂-CH₃), 2.87 – 3.00 (m, 4H, CH₂-CH₂), 4.23-4.33 (m, 4H, 2x OCH₂-CH₃), 6.50 (broad s, 2H, NH₂ deuterium oxide exchangeable), 7.27 (s, 1H, 2-H), 7.31 – 7.37 (m, 2H, 3'-H and 5'-H), 7.82 – 7.88 (m, 2H, 2'-H and 6'-H), 8.21 ppm (s, 1H, 5H); ms: m/z 342 (M⁺).

Anal. Calcd. for C₁₉H₂₂N₂O₄: C, 66.66; H, 6.48; N, 8.18. Found: C, 67.05; H, 6.74; N, 8.57.

Methyl 4-[2-(5-Amino-4-carbamoylpyridin-2-yl)ethyl]benzoate (8).

A solution of 500 mg (1.67 mmoles) **7** in 50 ml methanol was saturated with ammonia at 0 °C for 15 minutes. The mixture was kept in an autoclave at 80 °C overnight, cooled to room temperature and evaporated to dryness. The residue was separated by flash chromatography on silica gel (cyclohexane:ethyl acetate 5:5, v/v), yield 300 mg (60%). mp 173 – 175 °C; ir (potassium bromide): 3430, 3340 and 3186 (NH), 2952, 2925 and 2859 (CH), 1718 (ester CO), 1669 cm⁻¹ (amide CO); ¹H nmr (dimethylsulfoxide-d₆): δ 2.84-2.93 and 2.98-3.07 (m, 4H, CH₂-CH₂), 3.83 (s, 1H, OCH₃), 6.38 (broad s, 2H, NH₂ deuterium oxide exchangeable), 7.31 (s, 1H, 2-H), 7.33-7.37 (m, 2H, 3'-H and 5'-H), 7.39 (broad s, 1H, CONH, deuterium oxide exchangeable), 7.84-7.89 (m, 2H, 2'-H and 6'-H), 7.94 (broad s, 1H, CONH, deuterium oxide exchangeable), 8.06 ppm (s, 1H, 5-H); ms: m/z 299 (M⁺).

Anal. Calcd. for C₁₆H₁₇N₃O₃: C, 64.21; H, 5.72; N, 14.04. Found: C, 63.98; H, 5.68; N, 13.86.

Methyl 4-[2-(2-Amino-4-oxopyrido[3,4-d]pyrimidin-6-yl)ethyl]benzoate (10).

A mixture of 50 mg (0.16 mmoles) **8**, 60 mg (0.53 mmoles) of freshly prepared chloroformamide hydrochloride (**9**) and 50 mg of dimethylsulfoxide was heated for 1 hour at 160 °C in an open flask with magnetic stirring. Water was added to the solid mass and, following warming this mixture, ammonium hydroxide 10% was added until neutralisation was achieved. The resulting white solid was isolated by filtration in a yield of 39 mg (40%); mp > 260 °C; ir (potassium bromide): 3334 and 3176 (NH), 1718 (ester CO), 1655 cm⁻¹ (CO); ¹H nmr (dimethylsulfoxide-d₆): δ 3.04-3.12 (m, 4H, CH₂-CH₂), 3.82 (s, 3H, OCH₃), 6.62 (broad s, 2H, NH₂ deuterium oxide exchangeable), 7.34-7.40 (m, 2H, 3'-H and 5'-H), 7.52 (s, 1H, 8-H), 7.82-7.89 (m, 2H, 2'-H and 6'-H), 8.56 ppm (s, 1H, 5-H); ms: m/z 324 (M⁺).

Anal. Calcd. for C₁₇H₁₆N₄O₃: C, 62.96; H, 4.97; N, 17.28. Found: C, 63.34; H, 5.25; N, 17.34.

Diethyl N-[4-[2-(2-Amino-4-oxopyrido[3,4-d]pyrimidin-6-yl)ethyl]-benzoyl]-L-glutamate (13).

The acid **11** was achieved from methyl 4-[2-(2-amino-4-oxopyrido[3,4-d]pyrimidin-6-yl)ethyl]benzoate (**10**) by stirring in 2 N sodium hydroxide at room temperature for 4 hours followed by neutralisation with glacial acetic acid. Compound **11** was obtained in an amorphous modification at 0 °C, collected by filtration, dried under vacuum and used without further purification.

To a suspension of 100 mg (0.33 mmoles) **11** in 7 ml dimethylformamide at 25 °C was added 0.042 ml (0.38 mmoles) N-methylmorpholine followed by 73 mg (0.39 mmoles) 6-chloro-2,4-dimethoxy-1,3,5-triazine and the resulting solution was stirred at 25 °C for 1 hour. N-methylmorpholine (0.06 ml, 0.54 mmoles) was added to the solution followed by 83 mg (0.35 mmoles) diethyl L-glutamate hydrochloride, and the resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated *in vacuo* and the residue was taken up in 7 ml dichloromethane. The dichloromethane layer was washed with 5% NaHCO₃, dried (MgSO₄) and concentrated *in vacuo*. The residue was chromatographed on silica gel eluting with chloroform:methanol (95:5, v/v) to give 130 mg (80%) as a white solid. mp 215-217 °C; ir (sodium chloride): 3297 (NH), 2981 and 2935 (CH), 1735 (ester CO), 1662 cm⁻¹ (CO); ¹H nmr (dimethylsulfoxide-d₆): δ 1.13-1.21 (m, 6H, 2x OCH₂-CH₃), 1.93-2.16 and 2.40-2.46 (m, 4H, ethyl glutamate CH₂-CH₂), 3.07 (s, 4H, aryl CH₂-CH₂), 3.99-4.14 (m, 4H, 2x OCH₂-CH₃), 4.37-4.46 (m, 1H, ethyl glutamate HCNH₂), 6.52 (broad s, 2H, NH₂ deuterium oxide exchangeable), 7.29-7.35 (m, 2H, 3'-H and 5'-H), 7.54 (s, 1H, 8-H), 7.75-7.79 (m, 2H, 2'-H and 6'-H), 8.56 (s, 1H, 5-H), 8.60-8.64 (d, 1H, CONH); 11.21 ppm (broad s, 1H, NH, deuterium oxide exchangeable); ms: m/z 495 (M⁺).

Anal. Calcd. for C₂₅H₂₉N₅O₆: C, 60.60; H, 5.90; N, 14.13. Found: C, 60.60; H, 6.18; N, 14.42.

N-[4-[2-(2-Amino-4-oxopyrido[3,4-d]pyrimidin-6-yl)ethyl]benzoyl]-L-glutamic Acid (14).

A solution of 50 mg (0.1 mmoles) of **13** in 1 ml 2 N sodium hydroxide was allowed to stir at room temperature for 24 hours. The reaction mixture was acidified with glacial acetic acid and the solid product was collected by filtration, washed with water and dried to give 29 mg (65%) as a white solid. mp 254-255 °C (decomposition); ir (sodium chloride): 3316 (NH); 2981 and 2931 (CH); 1725 cm⁻¹ (CO); ¹H nmr (F₃CCOOD): δ 2.37-2.59 and 2.65-2.90 (m, 4H, ethyl glutamate CH₂-CH₂), 3.15-3.24 and 3.75-3.88 (m, 4H, aryl CH₂-CH₂), 5.07-5.17 (m, 1H, ethyl glutamate HCNH₂), 7.45 (s, 1H, 8-H), 7.49-7.55 (m, 2H, 3'-H and 5'-H), 7.80-7.94 (m, 2H, 2'-H and 6'-H), 8.58 ppm (s, 1H, 5-H); ms: m/z 440 (M+1).

Anal. Calcd. for C₂₁H₂₁N₅O₆: C, 57.41; H, 4.82; N, 15.94. Found: C, 57.36; H, 4.73; N, 16.15.

Methyl 4-[2-(5-Amino-4-cyanopyridin-2-yl)ethyl]benzoate (15).

Triethylamine (126 mg, 1.25 mmoles) were added to a solution of 60 mg (0.20 mmoles) **8** at 0 °C in 2 ml tetrahydrofuran (THF) followed by 160 mg trifluoroacetic anhydride in 1 ml THF. After 30 minutes 2 ml water was added, and the mixture was extracted with 2 x 2 ml diethyl ether. The organic layer was dried and evaporated, and the residue was dissolved in 2 ml methanol-water (1:1) containing 100 mg K₂CO₃. The mixture was heated at 70 °C for 24 hours, cooled, and extracted with 2 x 2 ml ethyl acetate. The extracts were washed with water and brine, dried, and evaporated to give 50 mg (90%); mp 128-129 °C; ir (sodium chloride): 3436 and 3359 (NH), 2923 and 2854 (CH), 2217 (CN), 1712 cm⁻¹ (ester CO); ¹H nmr (dimethylsulfoxide-d₆): δ 2.85-2.93 and 2.94-3.05 (m, 4H, CH₂-CH₂), 3.84 (s, 3H, OCH₃), 6.22 (broad s, 2H, NH₂ deuterium oxide exchangeable), 7.21 (s, 1H, 2-H), 7.30-7.44 (m, 2H, 3'-H and 5'-H), 7.82-7.91 (m, 2H, 2'-H and 6'-H), 8.20 ppm (s, 1H, 5-H); ms: m/z 281 (M⁺).

Anal. Calcd. for C₁₇H₁₇N₃O₂: C, 69.14; H, 5.80; N, 14.23. Found: C, 68.85; H, 5.91; N, 14.17.

Methyl 4-[2-(2,4-Diaminopyrido[3,4-*d*]pyrimidin-6-yl)ethyl]-benzoate (**17**).

Compound **15** (35 mg, 0.12 mmoles) were dissolved at 130 °C in 250 mg dimethylsulfone. After addition of 40 mg (0.68 mmoles) guanidine (**16**), the mixture was stirred at this temperature for 1.5 days. The hot solution was diluted with 0.5 ml water, the solid thus obtained was collected by filtration and chromatographed on silica gel eluting with chloroform:methanol (9:1, v/v) to give 20 mg (50%); mp 286-288 °C; ir (sodium chloride): 3548 and 3336 (NH), 2919 and 2854 (CH), 1751 cm⁻¹ (CO); uv (methanol): $\lambda_{\max}$ 345 nm (ϵ 8591); ¹H nmr (dimethylsulfoxide-*d*₆): δ 2.84-2.92 and 3.27-3.40 (m, 4H, CH₂-CH₂), 3.72 (s, 3H, OCH₃), 6.26 (broad s, 2H, NH₂, deuterium oxide exchangeable), 6.80 (s, 1H, 8-H), 6.82-6.85 (m, 2H, 3'-H and 5'-H), 6.94 (broad s, 2H, NH₂, deuterium oxide exchangeable), 7.12-7.19 (m, 2H, 2'-H and 6'-H), 8.43 ppm (s, 1H, 5-H); ms: m/z 323 (M⁺).

Anal. Calcd. for C₁₇H₁₇N₅O₂: C, 63.15; H, 5.30; N, 21.66. Found: C, 63.42; H, 5.18; N, 21.34.

Diethyl N-[4-[2-(2,4-Diaminopyrido[3,4-*d*]pyrimidin-6-yl)ethyl]benzoyl]-L-glutamate (**19**).

Preparation and purification according to **11** from 50 mg (0.16 mmoles) **17** via the acid **18** yielded 51 mg (65%) **19** as a white solid; mp 220-221 °C; ir (sodium chloride): 3409 and 3286 (NH); 2981 and 2931 (CH); 1735 cm⁻¹ (CO); ¹H nmr (dimethylsulfoxide-*d*₆): δ 1.12-1.23 (m, 6H, 2x OCH₂-CH₃), 1.95-2.16 and 2.39-2.46 (m, 4H, ethyl glutamate CH₂-CH₂), 2.96-3.08 and 3.37-3.50 (m, 4H, aryl CH₂-CH₂), 4.01-4.15 (m, 4H, 2x OCH₂-CH₃), 4.38-4.48 (m, 1H, ethyl glutamate HCNH₂), 6.44 (broad s, 2H, NH₂, deuterium oxide exchangeable), 6.84 (s, 1H, 8-H), 7.15 (broad s, 2H, NH₂, deuterium oxide exchangeable), 7.28-7.36 (m, 2H, 3'-H and 5'-H), 7.75-7.83 (m, 2H, 2'-H and 6'-H), 8.44 (s, 1H, 5-H), 8.61-8.68 (d, 1H, CONH); ms: m/z 494 (M⁺).

Anal. Calcd. for C₂₅H₃₀N₆O₅: C, 60.72; H, 6.11; N, 17.00. Found: C, 60.79; H, 5.94; N, 17.32.

N-[4-[2-(2,4-Diaminopyrido[3,4-*d*]pyrimidin-6-yl)ethyl]benzoyl]-L-glutamic Acid (**20**).

Preparation and purification according to **14** from 50 mg (0.10 mmoles) **19** yielded 31 mg (71%) **20** as a white solid; mp 268-269 °C (decomposition); ir (sodium chloride): 3374 and 3313 (OH, NH), 2981 and 2935 (CH), 1715 cm⁻¹ (CO); ¹H nmr (dimethylsulfoxide-*d*₆): δ 1.89-2.15 and 2.25-2.40 (m, 4H, ethyl glutamate CH₂-CH₂), 2.90-3.09 and 3.35-3.50 (m, 4H, aryl CH₂-CH₂), 4.26-4.43 (m, 1H, ethyl glutamate HCNH₂), 6.54-6.80 (broad s, 1H, NH₂, deuterium oxide exchangeable), 6.89 (s, 1H, 8-H), 7.25-7.39 (m, 2H, 3'-H and 5'-H), 7.74-7.85 (m, 2H, 2'-H and 6'-H), 8.41-8.54 ppm (m, 2H, 5-H and CONH); ms: m/z 439 (M+1).

Anal. Calcd. for C₂₁H₂₂N₆O₅: C, 57.53; H, 5.06; N, 19.17. Found: C, 57.38; H, 5.26; N, 19.04.

REFERENCES AND NOTES

- [1] A. L. Jackson, *Antifolate Drugs in Cancer Therapy*, Humana Press, Totowa, New Jersey, 1999.
- [2] A. Rosowski, *Progress in Medical Chemistry*, Edt. by G. Ellis and G. B. West, Elsevier, Amsterdam, **26**, 1 (1989).
- [3] A. Graul, M. Tracy and J. Castañer, *Drugs Fut.*, **23**, 498 (1998).
- [4] P. Karlson, *Biochemie*, 13. Auflage, Georg Thieme Verlag, Stuttgart - New York 1988, pp 94-97.
- [5] E. C. Taylor, P. J. Harrington, S. R. Fletcher, G. P. Beardsley and R. G. Moran, *J. Med. Chem.*, **28**, 914 (1985).
- [6] J. R. Piper, G. S. McCaleb, J. A. Montgomery, R. L. Kisliuk, Y. Gaumont and F. M. Sirotak, *J. Med. Chem.*, **29**, 1080 (1986).
- [7] M. S. Ray, F. M. Muggia, G. C. Leichman, R. L. Nelson, R. W. Dyke and R. G. Moran, *J. Natl. Cancer Inst.*, **85**, 1154 (1993).
- [8] E. M. Grivsky, S. Lee, C. W. Sigel, D. S. Duch and C. A. Nichol, *J. Med. Chem.*, **23**, 327 (1980).
- [9] J. H. Maguire and R. L. McKee, *J. Heterocyclic Chem.*, **16**, 133 (1979).
- [10] Z. Ozdowska and B. Szczyński, *Rocz. Chem.*, **50**, 1771 (1976).
- [11] R. G. Glushkov, O. Ya Belyaeva, V. G. Granik, M. K. Polievktova, A. B. Girgorev, V. E. Serokhvostova and T. F. Vlasova, *Khim. Geterotsikl. Soedin.*, 1640 (1976).
- [12] D. J. Berry, J. D. Cook and B. J. Wakefield, *J. Chem. Soc., Perkin Trans. 1*, 2190 (1972).
- [13] R. Madhav, *Org. Prep. Proced. Int.*, **14**, 403 (1982).
- [14] D. G. Batt and G. C. Houghton, *J. Heterocyclic Chem.*, **32**, 963 (1995).
- [15] G. W. Rewcastle, W. A. Denny, R. T. Winters, N. L. Colbry, and H. D. Hollis Showalter, *J. Chem. Soc., Perkin Trans. 1*, 2221 (1996).
- [16] R. Troschütz and A. Lückel, *Arch. Pharm. (Weinheim)*, **324**, 73 (1991).
- [17] R. Troschütz and A. Karger, *J. Heterocyclic Chem.*, **33**, 1815 (1996).
- [18] J. J. Parlow, D. A. Mischke and S. S. Woodard, *J. Org. Chem.*, **62**, 17; 5908 (1997).
- [19] V. Ojea, C. Peinador and J. M. Quintela, *Synthesis*, 798 (1992).
- [20] A. Tanaka, T. Terasawa, H. Hagihara, N. Ishibe, M. Sawada, Y. Sakuma, M. Hashimoto, H. Takasugi and H. Tanaka, *J. Med. Chem.*, **41**, 4408 (1998).
- [21] S. W. Schneller and A. C. Ibay, *J. Org. Chem.*, **51**, 4067 (1986).
- [22] E. C. Taylor and P. M. Harrington, *J. Org. Chem.*, **55**, 3222 (1990).
- [23] E. C. Taylor, H. H. Patel, G. Sabitha and R. Chaudhari, *Heterocycles*, **43**, 349 (1996).
- [24] G. A. Olah, S. C. Narang, A. P. Fung and B. G. B. Gupta, *Synthesis*, 657 (1980).
- [25] D. A. Claremon and B. T. Phillips, *Tetrahedron Letters*, **29**, 2155 (1988).
- [26] K. E. Andersen and E. B. Pedersen, *Liebigs. Ann. Chem.*, 1012 (1986).
- [27] M. Rowley, J. J. Kulagowski, A. P. Watt, D. Rathbone, G. I. Stevenson, R. W. Carling, R. Baker, G. R. Marshall, J. A. Kemp, A. C. Foster, S. Grimwood, R. Hargreaves, C. Hurley, K. L. Saywell, M. D. Tricklebank and P. D. Leeson, *J. Med. Chem.*, **40**, 4053 (1997).
- [28] F. Schönfeld and R. Troschütz, *Heterocycles*, **55**, 1679 (2001).